



ADULT LYMPHOMA / LEUKEMIA T: PREVALENT ENTITY IN SOUTH AMERICA

LINFOMA/LEUCEMIA T DEL ADULTO: ENTIDAD PREVALENTE EN SUDAMÉRICA

Brady E. Beltran¹, Jorge Castillo^{2,3}

Adult T - lymphoma / leukemia is an aggressive T lymphoproliferative entity associated retrovirus HTLV-1-T.

HTLV-1 infection is endemic in Japan, the Caribbean, Africa, South America, and the Middle East. In South America, we have Peru, Brazil, Colombia and Chile.

Peru is endemic for this virus⁽¹⁻³⁾. The prevalence of retroviruses in Europe and the USA. USA It is less than 1% but in Peru it is estimated that around 3% of the healthy adult population is a carrier of the retrovirus^(4,5).

From Chile, there have been several ATLL reports since 1992 by Dra. Cabrera et al.^(6,7,8).

Other diseases caused by retroviruses include tropical spastic paraparesis, uveitis, infectious dermatitis, and other rheumatologic, psychiatric, and infectious disorders⁽⁹⁾.

Only 2% to 4% of virus carriers will develop ATLL⁽¹⁰⁾. The viral genes involved in the malignant transformation are Tax and HBZ^(11,12).

Five clinical types are identified in this disease: latent, chronic, cutaneous, lymphomatous, and acute. However, the acute and lymphomatous forms are the most aggressive and also the most prevalent.

As to prognosis, the poor prognosis factors are: clinical stage, performance status, age, albumin, and soluble IL-2 receptor⁽¹³⁾.

The survival of the acute forms can be 2 months, while the lymphomatous forms can have a survival time of around 9 months.

Treatment for leukemic forms is Interferon alfa and zidovudine; the lymphomatous form responds to chemotherapy^(14,15). Allogeneic transplantation may be the only curative form of the disease.

In this issue of the journal, a complete review of this entity is presented by Dra. Cabrera et al.

EDITORIAL

Correspondence: Brady E. Beltrán.

Address: Av. Edgardo Rebagliati 490, Jesús María 15072, Lima - Perú

Telephone: +51 999539061

E-mail: bgbrady@hotmail.com

¹ Lymphoma Unit - Medical Oncology Service. Social Security National Hospital Edgardo Rebagliati Martins, Lima-Perú.

² Bing Center for Waldenstrom Macroglobulinemia.

³ Division of Hematological Malignancies, Dana-Farber Cancer Institute.

Cite as: Brady E. Beltran. Adult lymphoma / Leukemia T: prevalent entity in south america. Rev Rev. Fac. Med. Hum. April 2020; 20(2):178-179.

DOI 10.25176/RFMH.v20i2.2914

BIBLIOGRAPHIC REFERENCES

1. Carrasco A., Beltrán B et al. Clinical and phenotypic characteristics of adult t-cell leukemia / lymphoma – report of 36 cases in Lima-Perú. Proceeding book EHA 2001, poster.
2. Pimentel P, Beltrán B, Carrasco A. Clinical characteristics of lymphomatous form of adult t-cell lymphoma-leukemia in Peru. Proceedings book ASCO 2005, abstract 6728.
3. Beltran B, Carrasco A. Clinical outcomes in adult t-cell leukemia / lymphoma: report of 55 cases from Peru. Proceeding book ASH 2005, abstract 479.
4. Sanchez-Palacios C, et al. Seroprevalence and risk factors for human t-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. International Journal of Infectious Diseases 2003; 7: 132-137.
5. Alarcón Jo, et al. High endemicity of human t-cell lymphotropic virus type 1 among pregnant women in Peru. Journal of Acquired Immune Deficiency Syndromes 2006; 42: 604-609.
6. Cabrera M, Gray AM, Cartier I, et al. Simultaneous adult t-cell leukemia/lymphoma and sub-acute polyneuropathy in a patient from Chile. Leukemia 1991; 5: 350-353.
7. Cabrera Mec, Majlis AL, Labra SG, et al. Estudio inmunológico de enfermedades linfoproliferativas. Rev ME'd Chile 1992; 120: 772-777.
8. Cabrera ME, Labra S, Catovsky D, et al. HTLV-I positive adult t-cell leukaemia/lymphoma (ATLL) in Chile. Leukemia 1994; 8: 1763-1767.
9. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, et al. Oncogene. Global epidemiology of HTLV-I infection and associated diseases 2005; 24(39):6058-68.
10. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 100B. Biological Agents. Lyon (France): IARC; 2012. Available at: <http://monographs.iarc.fr/ENG/Monographs/vol100B/>
11. Brand H, Alves JGB, Pedrosa F, Lucena-Silva N. Leucemia de células T do adulto. Rev Bras Hematol Hemoter. 2009; 31(5):375-83.
12. Matsuoka M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology. 2005; 2:27.
13. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012; 30(14):1635-40 12.
14. Ministério da Saúde – Secretaria de Vigilância da Saúde. Portaria n. 54 de 18/07/2016 – Aprova o Protocolo de Uso da Zidovudina para Tratamento do Adulto com Leucemia/Linfoma Associação ao Vírus HTLV-1. Diário Oficial da União. 2016. Available in: http://bvsms.saude.gov.br/bvs/saudelegis/svs/2016/prt0054_18_07_2016.html.
15. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010; 28(27):4177-83.

Indexed in:



http://www.scielo.org.pe/scielo.php?script=sci_serial&pid=2308-0531&lng=es&nrm=iso



<https://network.bepress.com/>



<https://doaj.org/>



<http://lilacs.bvsalud.org/es/2017/07/10/revis-tas-indizadas-en-lilacs/>

